Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
The Goodman raising, the ASX’s sixth-largest ever and the bourse’s largest real estate deal, was done unsounded and with no ...
Aviation Facilities Company Management, LLC (“AFCO”), an independent industry leader in the investment, development, management and operation of on-airport cargo ...
In a report released on February 14, Luca Issi from RBC Capital maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...
Goldman Sachs has appointed insiders William Connolly and Michael Voris as co-heads of Equity Capital Markets (ECM) in the ...
Bloomberg Gawler started his investment banking career in JPMorgan’s industrials team before jumping to Deutsche Bank and RBC Capital Markets. He joined Goldman Sachs in 2021, and picked up ...
That said, the stock has been on fire, surging 116% since November 2023 as the investment bank crushed earnings expectations last year. Looking ahead, Goldman Sachs anticipates a meaningful shift that ...
Goldman Sachs is poised to benefit from an anticipated resurgence in capital markets activity. Analysts are optimistic about the company's prospects in this core area of its business, with several ...
Goldman Sachs Emerging Markets Credit Fd earns an Average Process ... The investment seeks a high level of total return consisting of income and capital appreciation. The fund invests, under ...
Goldman Sachs would consider acquisitions in asset and wealth management, but would be highly selective about any deal, CEO ...